Roth Capital is bookrunning manager; co-manager Monarch assists
By Devika Patel
Knoxville, Tenn., July 16 – iRadimed Corp. priced its $12.6 million initial public sale of stock with a $1.01 million greenshoe, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission. The deal was announced on June 18.
The company will sell 2,016,000 common shares at $6.25 apiece.
Roth Capital Partners is the bookrunning manager.
Settlement is expected on July 21.
Proceeds will be used for sales and marketing efforts, research and development, working capital and other general corporate purposes.
The provider of non-magnetic intravenous infusion pump systems is based in Winter Springs, Fla. The company intends to list its common stock on the Nasdaq under the symbol “IRMD.”
| Issuer: | iRadimed Corp.
|
| Issue: | Common stock
|
| Amount: | $12.6 million
|
| Greenshoe: | $1,012,500
|
| Shares: | 2,016,000
|
| Price: | $6.25
|
| Warrants: | No
|
| Bookrunner: | Roth Capital Partners
|
| Co-manager: | Monarch Capital Group
|
| Announcement date: | June 18
|
| Pricing date: | July 16
|
| Settlement date: | July 21
|
| Stock symbol: | Nasdaq: IRMD
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
